CSIMarket Company Name, Ticker, Competitors, else..
 
Senti Biosciences Holdings Inc   (NASDAQ: SNTI)
 
Price: $0.3049 $0.00 -0.359%
Day's High: $0.3100000023841858 Week Perf: -3.51 %
Day's Low: $ 0.30 30 Day Perf: -20.6 %
Volume (M): 26,607 52 Wk High: $ 2.88
Volume (M$): $ 0 52 Wk Avg: $1.10
Open: $0.31 52 Wk Low: $0.29



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 31
 Employees 39
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0

Business Description


Senti Biosciences Inc is a biotechnology company that specializes in developing synthetic biology platforms for advancing healthcare solutions. They focus on engineering cell and gene therapies to cure a variety of diseases by programming cells to detect and respond to specific signals within the body. Their innovative technology allows for precise control over cellular behaviors, enabling targeted therapies with enhanced safety and efficacy. Senti Biosciences Inc aims to revolutionize the field of medicine by harnessing the power of synthetic biology to create personalized treatments for patients.


   Company Address: 2 Corporate Drive, First Floor South San Francisco 94080 CA
   Company Phone Number: 239-2030   Stock Exchange / Ticker: NASDAQ SNTI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -5.23%    
BEAM   -17.43%    
GILD   -3.88%    
LCTX   -3.24%    
LENZ   -25.59%    
MGTX   -7.06%    
• View Complete Report
   



Clinical Study

Innovative Frontiers in Cancer Immunotherapy Senti Bios Groundbreaking Clinical Trials for Hepatocellular Carcinoma ...

Published Sun, Dec 29 2024 7:57 PM UTC

The landscape of cancer treatment is undergoing a transformative evolution as innovative therapies harness the immune system s capabilities. With an increasing emphasis on personalized medicine and cellular therapies, Senti Biosciences, Inc. is at the forefront of these advancements. Recent news highlights two promising developments from the company: the initiation of a clin...
Shares

Senti Biosciences Fortifies Talent Pool With Stock Options Amid Strategic Shift,

Published Wed, Dec 4 2024 1:00 AM UTC

Senti Biosciences Announces Employee Inducement Grants Amid Strategic RestructuringIn a move aimed at bolstering its workforce, Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering clinical-stage biotechnology firm, has announced the issuance of stock options to new employees. The announcement came on December 3, 2024, marking a significant step in the company s strategic e...
Shares

Senti Bio Boosts Share Value with Reverse Stock Split: Shares to Begin Trading on a Split-Adjusted Basis on July 18, 2024.

Published Tue, Jul 16 2024 12:30 PM UTC

Senti Bio Announces Reverse Stock Split: Shares Expected to Begin Trading on Split-Adjusted Basis on July 18, 2024
Senti Bio, a leading biotechnology company, made an exciting announcement today regarding their upcoming reverse stock split. The company revealed that shares are expected to begin trading on a split-adjusted basis on July 18, 2024. This move symbolizes an i...
Financing Agreement

Senti Bio Secures $8 Million Grant to Advance Clinical Development of Regenerative Therapy

Published Mon, Jul 1 2024 12:06 PM UTC



In a groundbreaking move for the field of regenerative medicine, the California Institute for Regenerative Medicines (CIRM) has announced an $8 million grant to Senti Bio. The generous funding is intended to support the clinical development of SENTI-202, a logic gated CAR-NK cell therapy. This development comes amidst positive financial indicators for Senti Bioscie...
Clinical Study

SENTI-202 Commences Phase 1 Clinical Trial: A Promising Breakthrough in Hematologic Malignancy Treatment

Published Mon, May 13 2024 12:16 PM UTC

CSIMarket.com aims to provide a comprehensive overview of the latest advancements in the field of pharmaceutical research and development. In accordance with this , this article sheds light on a groundbreaking development concerning the commencement of Phase 1 clinical trials for SENTI-202, a novel treatment for relapsed or refractory hematologic malignancies, including Ac...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 172.66
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.83
Working Capital Ratio 0.87
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.88 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 0.42 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,410
Net Income per Employee (TTM) -1,270,872
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -85229.41 %
Net Margin (MRQ) -75000 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Senti Biosciences Holdings Inc's Segments
Reportable Segment    194.12 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.